Growth Hormone & IGF Axis
Browse GH/IGF-axis compounds and distinguish hormone release from clinical outcomes.
How to read this page
Topic and body-area searches help discovery. They do not imply that evidence from one population, route or body site transfers to another.
Relevant compounds
Search all →
CJC-1295 (with DAC)
Early human pharmacology with regulator safety concerns; unapproved
Modified GRF(1-29) / 'CJC without DAC'
Direct human evidence gap; related-molecule human pharmacology only
CJC without DAC + Ipamorelin blend
Blend — component evidence only; no direct blend trial identified
Ipamorelin
Human Phase I/II exposure; tested Phase II indication was negative; no lifestyle eff…
GHRP-2
Limited human physiology / endocrine evidence; lifestyle efficacy unproven
GHRP-6
Limited human pharmacology / endocrine evidence; clinical lifestyle efficacy unproven
Hexarelin
Limited human endocrine/sleep physiology; lifestyle efficacy unproven
Sermorelin
Established human endocrine pharmacology; historical clinical use; lifestyle benefit…
Somatropin (recombinant human growth hormone)
Approved medicine for defined indications; healthy-person anti-ageing use has limite…
Long R3 IGF-1
Preclinical/biochemical evidence with human therapeutic-efficacy gap
PEG-MGF
No human drug exposure identified; related in-vitro evidence conflicting
Tesamorelin
Approved narrow indication with additional randomized human metabolic evidence